Azora Therapeutics (AZR) vs Kazia Therapeutics (KZIA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Kazia Therapeutics is the larger company by market cap ($56.2 million vs $55.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AZR | KZIA |
|---|---|---|
| Share price | $3.85 | $4.92 |
| Market cap | $55.00M | $56.22M |
| 1-day change | -0.52% | -8.38% |
| YTD return | — | -28.59% |
| 1-year return | — | -41.08% |
| 5-year return | — | -99.01% |
| EPS (TTM) | $-18.09 | $-6.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-7.98M | — |
| 52-week high | $8.25 | $17.40 |
| 52-week low | $1.31 | $4.50 |
| Distance from 52-week high | -53.33% | -71.72% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +476.02% |
| Average volume | 50.12K | 307.30K |
| Shares outstanding | 14.29M | 11.43M |
| Employees | — | 6 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Kazia Therapeutics
KZIA stock →Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
AZR vs KZIA FAQ
Which is bigger, Azora Therapeutics or Kazia Therapeutics?
Kazia Therapeutics (KZIA) is larger, with a market capitalization of $56.22M compared with $55.00M for Azora Therapeutics (AZR).
Are Azora Therapeutics and Kazia Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.